Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

The Retina Group of New York announced the availability of Eylea, the latest in a series of anti-VEGF medications for all patients with the wet form of age-related macular degeneration (AMD). The ...

May 23 (Reuters) - German drugmaker Bayer (BAYGn.DE), opens new tab on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment ...

Aug 6 (Reuters) - Regeneron Pharmaceuticals Inc's Eylea helped improve the vision of patients with diabetic macular edema (DME) significantly better than laser surgery in a pair of late-stage clinical ...

The FDA approved Regeneron’s Eylea to treat neovascular age-related macular degeneration, according to an OSN SuperSite report. According to Regeneron, the drug was under a priority review by the FDA, ...